文章：

骨髓增生异常肿瘤（MDS）中可测量（微小）残留病的现状与展望

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives

原文发布日期：15 April 2024

DOI: 10.3390/cancers16081503

类型: Article

开放获取: 是

英文摘要：

Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes.

摘要翻译： 

骨髓增生异常肿瘤（MDS）的传统研究主要依赖于血细胞计数、细胞遗传学及形态学评估。近年来，分子检测技术的引入显著提升了MDS的诊断能力。可测量（微小）残留病（MRD）在MDS中的作用正逐步明确，多项研究已采用分子生物学与流式细胞术进行相关探索。本综述将重点阐述MDS中MRD概念的发展演变，概述当前应用的各种检测技术，并对报告MRD及其与临床预后相关性的研究进行系统性梳理。

原文链接：

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives